SOURCE: StockCall


January 05, 2011 08:37 ET

Analyst Research on Immucor Inc. and AMAG Pharmaceuticals Inc. - Diagnostic Substances Sector Primed to Grow

JOHANNESBURG, SOUTH AFRICA--(Marketwire - January 5, 2011) - offers investors comprehensive research on the diagnostic substances industry and has completed analytical research on Immucor Inc. (NASDAQ: BLUD) and AMAG Pharmaceuticals Inc. (NASDAQ: AMAG). Register with us today at to have free access to these researches. 

Growth throughout the Diagnostic Substances sector which includes players like Immucor Inc. is anticipated to be strong during the coming decades as chronic diseases and an aging populace increase demand for their products. Booming diabetes rates throughout the country have analysts predicting an increased demand for things like blood glucose test strips. The diagnostic disposables market is predicted to grow 7.0% annually during the coming years. Investors looking for free research on Immucor Inc. are welcome to sign up at for our new report. is an online platform where investors doing their due-diligence on the diagnostic substances industry can have easy and free access to our analyst research and opinions on Immucor Inc. and AMAG Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at

The Diagnostic Substances sector is relatively new and, not surprisingly, a key factor to companies' success is innovation. For example, companies within the sector are working on many new ways to diagnose cancer. One area of research is into new breath tests that gauge how a patient's breath reacts to certain sensors. Another potential cancer diagnostic coming to market is blood testing. The ease of products like these could create an enormous demand in the marketplace and prove highly profitable. There has also been a lot of interest lately in new DNA diagnostic tests. Some analysts have gone as far as predicting a 17% annual growth in the genetic testing industry. Register now at to have free access to our reports on the diagnostic substances industry.

Like much of the health-care industry, this sector is exposed to the whims of the Food and Drug Administration. For example, one company within the sector, AMAG Pharmaceuticals Inc., recently saw its stock value plummet when the FDA announced that it potentially had to begin posting strong warning labels on its products. When it came out that the warning labels would not be as strong as initially believed, the stock regained some of its value. Investors looking for complimentary research on AMAG Pharmaceuticals Inc. are welcome to sign up at for our new report. 

Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information